
Sherrill Neff
Thanks to the city’s glut of local universities and pharmaceutical companies, Philadelphia is a wonderful environment for a biotech startup to begin and to exit.
However, with the lack of an IPO market and current economic conditions, statups often need hundreds of millions of dollars to see their idea from research product to sale to big pharma.
And that’s where Quaker BioVentures steps in.
Founded in 2003 by Ira Lubert, Brenda Gavin and Sherrill Neff, Quaker takes pride in keeping all of its investments local — and for good reason. Philadelphia benefits from being in the center of the perfect storm of plentiful university research combined with a large number of pharmaceutical companies having major local operations.
“It’s important we get to know the [big pharmaceutical companies] really well, that they are our friends socially and professionally,” says Neff. “It’s easier here than if we were sitting on the West coast trying to have that interaction.”
After raising $280 million in 2003 and an additional $420 in 2006, Quaker has invested in over 25 companies, most based in the tri-state area.
We talked to Founding Partner Sherrill Neff about why Quaker only invests locally, how the citiy’s biotech market has evolved and why he credits lion slaying as one of his hobbies.
Read more